acenocoumarol / Generic mfg. - LARVOL DELTA

Safety of contraception among women using anticoagulant therapy: an updated systematic review. (PubMed, Contraception) - "Women on anticoagulant therapy are at risk for recurrent thrombosis and bleeding, which might be further exacerbated with use of certain contraceptive methods. Additional evidence is needed on safety of concurrent use of anticoagulant medications and contraceptives."

Journal • Review • Cardiovascular • Hematological Disorders • Long-acting Reversible Contraceptives • Venous Thromboembolism

RISK OF ISCHAEMIC STROKE AND INTRACRANIAL BLEEDING WITH DIRECT-ACTING ORAL ANTICOAGULANTS AND WARFARIN COMPARED TO ACENOCOUMAROL (WSC 2025) - "Background and Aims: Most clinical trials and observational studies conducted with direct-acting oral anticoagulants (DOAC: dabigatran, rivaroxaban, apixaban and edoxaban) have used warfarin as the comparator drug. The results suggest that conclusions drawn from studies using warfarin as the reference drug should not be automatically extrapolated to acenocoumarol."

Atrial Fibrillation • Cardiovascular • Ischemic stroke

Monitoring and Follow-Up of Patients on Vitamin K Antagonist Oral Anticoagulant Therapy Using Artificial Intelligence: The AIto-Control Project. (PubMed, J Clin Med) - "Background: Vitamin K antagonist oral anticoagulant (VKA) therapy, using warfarin or acenocoumarol in our health system, is indicated, according to clinical guidelines, for the prophylaxis of thromboembolic events. Additionally, it aims to ease the workload on both primary care and hospital services. These outcomes will be achieved through the involvement of advanced practice nurses who will supervise app-based monitoring and patient education."

Journal • Cardiovascular

Personalized management of acenocoumarol dosage using eGFR: Analysis of INR data in a cohort of 204 patients. (PubMed, Int J Clin Pharmacol Ther) - "Renal function, as measured by BSA-adjusted eGFR, is a critical determinant of acenocoumarol dose requirements. These findings support the inclusion of renal function in future acenocoumarol dose calculators and emphasize the importance of individualized dosing strategies."

Journal • Chronic Kidney Disease • Nephrology • Renal Disease

Insights into the alteration of vaginal microbiota and metabolites in pregnant woman with preterm delivery: prospective cohort study. (PubMed, Front Cell Infect Microbiol) - "In addition, vaginal metabolomics-based LC-Orbitrap-MS/MS revealed that the contents of 2-Piperidone, Melphalan, N-acetylputrescine, Obatoclax, Eurostoside, Pregnanediol 3-O-glucuronide, O-Phospho-L-serine, 1-Kestose and N-arachidonylglycine were significantly decreased in the PrPG group compared with the PrTG group, while Acenocoumarol, Isopyrazam, Pentosidine, hexose, 7-Hydroxymitragynine, PE, Tamoxifen and 1-Deoxynojirimycin contents were significantly increased. These results suggest that specific bacterial species and metabolites may serve as potential biomarkers for preterm birth prediction, and approve the theoretical basis for the intervention of preterm birth."

Journal

Tyrosine Kinase Inhibitor Treatment of a Patient with Chronic Myeloid Leukemia and Congenital Thrombophilia. (PubMed, Hematol Rep) - "Case Presentation: A 33-year-old woman with congenital thrombophilia (type I protein S deficiency and heterozygous Factor V Leiden mutation) and a history of VTE on long-term anticoagulation with acenocoumarol presented with CML. She exhibited primary resistance to first-line imatinib and poor tolerance with suboptimal response to second-line bosutinib... This case highlights the importance of individualized, multidisciplinary management in CML patients with coexisting thrombophilia. Asciminib, with its favorable cardiovascular safety profile, represents a promising therapeutic option in high-risk patients where other TKIs may be contraindicated due to resistance, intolerance, or thrombotic risk."

Journal • Cardiovascular • Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Venous Thromboembolism • PROS1

Hemorrhage Risk Associated with Anticoagulant and Antiplatelet Drug Combinations: Insights from the USFDA Adverse Event Reporting System. (PubMed, J Clin Med) - "Anticoagulants analyzed included warfarin, rivaroxaban, dabigatran, apixaban, edoxaban, betrixaban, and acenocoumarol; antiplatelets included aspirin, clopidogrel, ticagrelor, cilostazol, prasugrel, and dipyridamole. While our findings highlight potential safety signals related to hemorrhage with antithrombotic drug combinations, they remain hypothesis-generating and should not be interpreted as causal associations. Instead, they provide an initial basis for further validation in well-designed clinical cohorts where comorbidities can be adequately accounted for."

Adverse events • Journal • Hematological Disorders

Thrombocheck: a drug-drug interactions guide for cardiologists prescribing antithrombotic therapy (ESC-WCC 2025) - " First, a clinical pharmacist and a physician independently analysed the literature on DDI for 8 AT: 5 OAC (rivaroxaban, apixaban, edoxaban, dabigatran and acenocoumarol) and 3 AA (clopidogrel, ticagrelor and prasugrel). Aspirin was excluded as it is not known for PK DDI... Antithrombotic therapies are susceptible to numerous DDI. This simple yet important tool can help cardiologists minimize significant DDI when prescribing new AT, guiding them toward safer et more effective treatment options."

Cardiovascular

The key determinants of oral anticoagulant treatment experience in atrial fibrillation patients (ESC-WCC 2025) - "NOACs were used by 53% of patients, mainly rivaroxaban (38%), apixaban (11%), and edoxaban (4%), while 47% used VKAs, primarily warfarin (25%) and acenocoumarol (22%). The study highlights that socioeconomic factors, particularly education level and household income, play a crucial role in the perceived convenience and satisfaction with OAC therapy in AF patients. Patients receiving VKA therapy reported lower treatment convenience, possibly due to the need for frequent monitoring and dietary restrictions.These findings underscore the importance of individualized patient support and education to optimize adherence and overall treatment experience in anticoagulated AF patients."

Clinical • Atrial Fibrillation • Cardiovascular • Dyslipidemia

ARGONAUT: Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus (clinicaltrials.gov) - P3 | N=340 | Active, not recruiting | Sponsor: Centre Hospitalier Universitaire de Nīmes | Recruiting ➔ Active, not recruiting | Trial completion date: Apr 2025 ➔ Feb 2026

Enrollment closed • Trial completion date • Cardiovascular • Heart Failure • Thrombosis

Comparative clinical outcomes of acenocoumarol versus direct oral anticoagulants (DOACs) and warfarin in patients with atrial fibrillation: real-world-evidence (SIESTA-A study). (PubMed, Front Pharmacol) - "The aim of this study was to evaluate the effectiveness and safety of direct oral anticoagulants (DOACs: dabigatran, rivaroxaban, apixaban and edoxaban) and warfarin versus acenocoumarol in patients with atrial fibrillation under real-world clinical practice conditions. Although DOACs were clearly associated with a lower risk of intracranial bleeding compared to acenocoumarol, our data did not reveal a significant reduction in thromboembolic events. Warfarin was found to be both less effective and less safe than acenocoumarol."

Clinical data • HEOR • Journal • Real-world evidence • Atrial Fibrillation • Cardiovascular • Gastroenterology • Ischemic stroke • Pulmonary Embolism • Respiratory Diseases

Acute Coronary Syndrome in a Young Woman With Protein S Deficiency and Von Willebrand Disease Type 1: A Case of Mixed Hemostatic Disorders. (PubMed, Cureus) - "She underwent percutaneous intervention with multiple stents and commenced anticoagulation therapy with acenocoumarol following the identification of partial protein S deficiency (56%)...The anticoagulant regimen was switched to dabigatran...The patient achieved a favorable clinical outcome, characterized by symptom resolution, an absence of new thrombotic or bleeding events, and partial biochemical recovery. This case highlights the importance of comprehensive hematological investigations in young patients presenting with atypical arterial thrombotic events."

Journal • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Hematological Disorders • Hemophilia • Myocardial Infarction • Thrombosis • PROS1

Optimization of vitamin K antagonist treatment: Near patient monitoring versus standard of care a parallel group clinical trial in older patients with atrial fibrillation. (PubMed, Eur J Clin Pharmacol) - "NPTM of VKA treatment in AF-patients does not result in an improved TTR when compared to SOC. All-cause death, total number of minor bleedings and all non-major bleedings may be reduced in NPTM, although the study was not powered for these secondary outcomes. Future studies are needed to determine the cost-effectiveness of NTPM versus SOC."

Journal • Atrial Fibrillation • Cardiovascular • Geriatric Disorders

A comparison of antiplatelet and oral anticoagulation strategies to prevent cerebral microembolism after transcatheter aortic valve implantation: the AUREA trial. (PubMed, EuroIntervention) - "In patients without an indication for OAC, an OAC strategy for 3 months post-TAVI did not show any benefit over an antiplatelet strategy in preventing cerebral microembolism. Patients treated with DAPT showed a lower mean volume of brain damage on DW-MRI during the 90 days following TAVI compared to those treated with acenocoumarol."

Clinical • Journal • Cardiovascular • CNS Disorders • Vascular Neurology

Cost-effectiveness of dabigatran for thromboembolic events prevention in atrial fibrillation patients in Chile. (PubMed, Cost Eff Resour Alloc) - "Dabigatran is cost-effective and dominates both rivaroxaban and apixaban at current publicly available prices in Chile. In addition, we expect dabigatran-idarucizumab is also expected to be cost-effective for Chilean health system when is compared against acenocoumarol-PCC as reversal agents."

HEOR • Journal • Atrial Fibrillation • Cardiovascular • Hematological Disorders

Long-Term Outcomes of Valve Replacement With Mechanical Prosthesis in Patients With Valvular Heart Disease: A Single-Center Retrospective Study. (PubMed, Cureus) - "Objective To assess the survival outcomes, postoperative complications, and reoperation rates in patients who underwent prosthetic mechanical valve replacement with acenocoumarol and low-dose aspirin (75 mg), with adequate International Normalized Ratio (INR) monitoring. However, early postoperative risks, especially in women and those with advanced heart failure, highlight the need for individualized care and close monitoring. Future research should aim to refine patient selection, explore sex-based outcome disparities, and optimize anticoagulation strategies to further improve survival and quality of life in this population."

Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure

GLANZMANN THROMBASTHENIA AND VENOUS THROMBOSIS : ABOUT 2 CASES (EHA 2025) - "In January 2023, he was admitted for the third episode of melena associated with severe anemia (hemoglobin drop to 5 g/dl) resistant to platelet and red cell transfusions, and continuous infusion of Esomeprazole. This situation necessitated four injections of Novoseven at a dose of 6 mg twice daily for four days, which successfully stopped the bleeding...In 2007, thrombophlebitis of the right lower limb was discovered, and treated with anti-vitamin K (Sintrom*), which was stopped after five months due to recurrent hemorrhagic syndrome and thrombosis permeability... Those observations showed that a severe thrombotic process may occur even in GT.The occurrence of venous thrombosis in our cases is due to the injection of recombinant factor VIIa and the central catheter in one case, and estrogen-progestogen therapy in the second case. The use of unfractionated heparin and low-molecular-weight heparin in the 1st case remains the treatment of choice while the role of new oral..."

Clinical • Anemia • Cardiovascular • Gastroenterology • Hematological Disorders • Pain • Pulmonary Embolism • Respiratory Diseases • Thrombosis

IDENTIFICATION OF NEW MOLECULAR MECHANISMS OF ANTITHROMBIN DEFICIENCY: RESULTS FROM A POLISH COHORT (EHA 2025) - "Thirteen probands (54.2%) received DOAC: six (25.1%) rivaroxaban (20 mg qd), five (20.8%) apixaban (2.5 mg or 5 mg bid) and two (8.3%) dabigatran (150 mg bid). Six probands were under anti-vitamin K treatments: four (16.7%) warfarin (8 or 10 mg qd) and two (8.3%) acenocoumarol (4 mg qd). Finally, four (16.7%) patients received antiplatelet therapy with acetylsalicylic acid (75 mg qd) and one (4.1%) received enoxaparin (150 mg/kg body weight qd).NGS detected SERPINC1 variants in 25 cases (86.2%): 12 missense (48%), 1 new (c.457T>C); 6 small deletions/insertions (24%), 2 new (c.962insG; c.402_403delGA+c.406_408+delGAGG), 5 intronic (20%) and 2 nonsense (8%)... Our study highlights the wide genetic heterogeneity involved in AT deficiency. We identified new genetic defects in SERPINC1, including intronic variants and confirmed the role of retrotransposon insertions as a new under-recognized mechanism contributing to congenital AT deficiency through in the genetic..."

Cardiovascular • Hematological Disorders • Respiratory Diseases • Venous Thromboembolism

Comparison of INR Values Obtained Using a Traditional Method and a Point-of-Care Device (ISTH 2025) - "Methods A total of 182 INR measurements from patients on vitamin K antagonists (acenocoumarol and warfarin) were grouped into three ranges: 1–1.99 (n=82), 2–3.5, (n=79) and >3.5 (n=21). Results The results are summarized in the Table 1 and Table 2High agreement was observed within the therapeutic range (2–3.5), while variability increased at INR levels >3.5, consistent with the sensitivity of thromboplastins to reduced vitamin K-dependent factors such as Factor VII. Table or Figure Upload"

A PHASE IB, MULTICENTRE, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SUBCUTANEOUSLY ADMINISTERED MOSUNETUZUMAB IN PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (EULAR 2025) - P1 | "Four of 15 patients experienced a total of 5 cytokine release syndrome (CRS) events; all were Grade 1-2 and none required tocilizumab administration...One patient receiving concomitant acenocoumarol experienced a transient increase in international normalised ratio due to expected cytochrome P450 inhibition by transient cytokine release, requiring acenocoumarol dose adjustment... Preliminary data from this Phase Ib study indicated that mosunetuzumab exhibits an acceptable safety profile in patients with SLE and that its PK profile in the SLE population is closely aligned with that observed in the relapsed or refractory NHL population. Deep B-cell depletion in the higher-dose cohorts demonstrated the potential for treating B-cell–driven autoimmune diseases. Whilst this study was designed to evaluate the safety and PK profile of mosunetuzumab with a limited dosing regimen, there did appear to be a positive impact on clinical activity."

Clinical • PK/PD data • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Inflammatory Arthritis • Interstitial Lung Disease • Lupus • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Respiratory Diseases • Systemic Lupus Erythematosus • CD4 • CD8

Obstructive Pharyngo-Laryngeal Hematoma Complicating Oral Anticoagulation: Case Report. (PubMed, Iran J Otorhinolaryngol) - "We present the case of a 74-year-old man who was on oral anticoagulation by acenocoumarol and presented with acute laryngeal dyspnea...Pharyngo-laryngeal hematoma should be considered in patients receiving anticoagulant therapy with symptoms of upper airway obstruction. Drug interactions may be the underlying cause of hypercoagulation, so medications should be carefully prescribed to these patients."

Journal • Hematological Disorders • Pulmonary Disease

Argatroban anticoagulation for heparin induced thrombocytopenia after Heartmate 3 implantation: a single center experience (HEART FAILURE 2025) - "Limited data exist on the management of those patients (most of the published cases use bivalirudin (5–8))...Patients 1 and 2 were successfully bridged to acenocoumarol (International Normalized Ratio range 2-2.5) and discharged without hemocompatibility-related adverse events (Table)...Patients with previous coagulation disturbances may represent a subset of high-risk patients for worse outcomes after HIT regardless of the use of argatroban. It is challenging to distinguish which adverse events are attributable to HIT and argatroban, and which are inherent to LVADs, as these devices themselves carry a high risk of thromboembolism, bleeding, and morbi-mortality."

Clinical • Cardiovascular

Quality of vitamin K antagonist treatment during the last year of life. (PubMed, Hemasphere) - "This decline was more pronounced in cancer patients and acenocoumarol users. In conclusion, the quality of VKA anticoagulation declined in the last year of life in severely ill patients, marked by reduced TTR and increased TAR and VGR, suggesting an increased bleeding risk. These findings highlight the importance of reassessing VKA use and considering discontinuation in patients approaching the end of life."

Journal • Cardiovascular • Heart Failure • Musculoskeletal Diseases • Oncology

Determining Drug Exposure Based on Medication Dispensing Data: A Validation Study of Vitamin K Antagonist Treatment Episodes Against INR Records. (PubMed, Pharmacoepidemiol Drug Saf) - "Fixed methods performed better than dynamic methods when classifying VKA exposure based on dispensing data. Our findings may guide other researchers working with VKA dispensing data, especially when the tablets dispensed or the prescribed dose are unavailable."

Journal

Management of Acenocoumarol in Tunisian elderly population : Risk factors of overdose and bleeding. (PubMed, Ann Cardiol Angeiol (Paris)) - "The use of anticoagulants in the elderly requires a comprehensive assessment, including comorbidities, geriatric settings, and social environment."

Journal • Atrial Fibrillation • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Peptic Ulcer • Renal Disease • Venous Thromboembolism